Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target reduced by UBS Group from $154.00 to $137.00 in a research report report published on Friday,Benzinga reports. They currently ...

UBS maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) but reduced its price target to $137 from $154, ...

Before joining Neurocrine, Dr. Keswani served as the President and Chief Executive Officer of Immunobrain, a clinical-stage ...

Neurocrine Biosciences, Inc. today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an ...

Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 /PRNewswire/ ...

Corient Private Wealth LLC grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 64.0% during the fourth quarter, according to the company in its most recent 13F filing with ...

Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds ...

Let's review some notable picks from our screened stocks. Overview: Neurocrine Biosciences, Inc. is engaged in the discovery, development, and marketing of pharmaceuticals targeting neurological, ...

WHITEHORSE, YT, March 20, 2025 /CNW/ - No one should have to choose between paying for prescription drugs and putting food on the table. That's why the Government of Canada is taking action so ...

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a biopharmaceutical company with a market capitalization of $11 billion and impressive revenue growth of nearly 25% over the last twelve months, ...